Just on the ABC Business tonight, Marcus Padley ( a top analyst) was saying BAL and BKL sell off is a bit over-reaction though any policy change in China means some uncertainty.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%